UpToDate vs DynaMed cost, evidence grades and which to buy

Neither is better in the abstract; they are built for different reading styles. DynaMed is faster to the recommendation because it is structured for it: a short overview, explicit recommendations and a stated level of evidence, so you can confirm the answer in seconds. UpToDate is richer because it walks you through the reasoning, which is why so many clinicians use it to actually learn a condition rather than just check one.

If your day is high-volume and you mostly need a quick, graded answer, DynaMed suits it. If you value the narrative and the depth, and you want to understand the argument behind the recommendation, UpToDate suits it. A number of clinicians who have access to both use DynaMed to move fast and UpToDate when they want the full picture.

For an individual, DynaMed is sold as DynaMedex, and EBSCO now prints the price on its own store. Checked at dynamedex.com in September 2026: DynaMedex is $599 a year and DynaMedex with Dyna AI is $675 a year, in US dollars, with the AI tier for individual subscribers available only in the USA. EBSCO says it prices by clinical role, that the student version is $149, and that every subscription runs one year and renews automatically on the anniversary date. There is a 30 day free trial and a 60 day money-back guarantee, which is a more generous return window than any other reference in this category offers.

Plain DynaMed, without the Micromedex drug content, is not on the individual store at all. It is licensed to hospitals, health systems and libraries, and the American College of Physicians provides DynaMedex to its members as a benefit, which for a US internist is often the cheapest legitimate route to it. The full breakdown by tier and by route is on our DynaMed and DynaMedex cost page.

Only one side of this comparison has a number. UpToDate publishes no individual price at any tier. We re-walked store.uptodate.com again this month: it asks for your country, then your role, then your profession, and the practicing-clinician route ends at a login before a figure appears. The annual figures on software directories are not vendor-sourced and disagree with each other, so we do not repeat them; what Wolters Kluwer does and does not publish is on our UpToDate subscription cost page.

So the honest cost comparison is $599 a year for DynaMedex against a quote for UpToDate. If you are buying on a CME allowance or a professional development fund that needs a figure before approval, DynaMedex is the one you can expense today. If your hospital already licenses UpToDate, which in the United States is the more common situation, the price is moot and the question is whether DynaMedex adds enough, mostly the Micromedex drug content and the concise format, to be worth $599 on top. BMJ Best Practice is the third reference in this position, and like DynaMedex it publishes a price.

The names cause real confusion at checkout. DynaMed Plus was the 2015 to 2019 name for the product; EBSCO dropped the Plus and it is simply DynaMed now. DynaMedex is DynaMed combined with Micromedex drug content from Merative, and it is the version an individual buys. So a search for DynaMed Plus vs UpToDate and a search for DynaMedex vs UpToDate are asking the same question about the same product line, and the comparison on this page covers both.

Against UpToDate specifically, DynaMedex is the stronger drug reference of the two only if you count Micromedex as part of it, because UpToDate ships its own drug database, Lexidrug, inside the same subscription. Both give you a disease reference and a drug reference under one login. The difference is that Micromedex is the one hospital pharmacists tend to verify orders against, and Lexidrug is the one more US prescribers already have through the chart. If you want that comparison on its own, read UpToDate vs Micromedex.

In the one controlled head-to-head we could find, they tied. A crossover study from the University of Toronto, published in the Journal of the Medical Library Association in 2021, gave 57 family medicine and obstetrics residents clinical questions to answer in each tool. Accuracy was level: an average of 1.35 correct answers out of 2 with UpToDate and 1.36 with DynaMed, a difference that was not statistically significant.

Speed was not level. Residents took 304 seconds on average to reach an answer in UpToDate and 459 seconds in DynaMed, so UpToDate was about two and a half minutes faster, and they reported more confidence in its answers. The authors add the caveat that matters for a buyer: 56 of the 57 residents had used UpToDate before and only 11 had used DynaMed. The study measured familiarity as much as design.

The practical reading is that neither product will give you a worse answer. If you trained on UpToDate, switching to DynaMedex to save money costs you some speed for the first months, and the 30 day trial is long enough to find out how much.

Both vendors now sell an AI layer over their own content, and they price it differently. EBSCO sells Dyna AI to individuals as a separate tier: DynaMedex with Dyna AI was $675 a year against $599 without it when we read the store in September 2026, and EBSCO states that the AI tier for individual subscribers is available in the USA only. You can see exactly what the AI costs you, which is $76 a year.

Wolters Kluwer puts UpToDate Expert AI inside UpToDate Pro Plus, the higher of its two individual plans, and in personal trainee subscriptions in the US. Neither plan has a published price, so the cost of the AI cannot be separated out. Expert AI answers from UpToDate topics only and links back to them, and it needs a connection even when the topic library is downloaded.

Both are closed systems by design: each answers from its own editorial content and nothing else. That is their advantage over a general chatbot, and it is also why a clinician who wants a second opinion across sources often keeps a free tool such as OpenEvidence alongside. We compare that route in OpenEvidence vs UpToDate.

Both are references you consult. Neither watches the prescription you are signing and tells you, unprompted, that the patient is already on an interacting drug, that their renal function makes the standard dose wrong, or that a documented allergy blocks the obvious choice. To get that you have to know to look, several separate times, and the errors that slip through are the checks nobody thought to run.

Prescriber.io is built for exactly that moment. Enter the drug or the scenario and it checks interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments and suggests guideline-based alternatives, together, with cited sources. It is decision-support, not autonomous prescribing: every flag is a prompt for the licensed clinician, who verifies against official sources and signs.